Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - AVADEL PHARMACEUTICALS PLCdreambigwalkpr_v3.htm
        





UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________

FORM 8-K
___________________

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 18, 2017
___________________

AVADEL PHARMACEUTICALS PLC
(Exact name of registrant as specified in its charter)
___________________

Ireland  
(State or Other Jurisdiction
of Incorporation)

000-28508 
(Commission File Number)
98-1341933
(I.R.S. Employer
Identification No.)
 
Block 10-1,  
Blanchardstown Corporate Park, Ballycoolin
Dublin 15, Ireland 
 (Address of Principal Executive Offices)
 


Not Applicable
(Zip Code)

 

Registrant’s telephone number, including area code: +353 1 485 1200
___________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o





If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 8.01 Other Events.
 
On May 17, 2017, Avadel Pharmaceuticals plc issued a press releases announcing its support off the Narcolepsy Network’s 5th Dream Big Walk in New York City and Seattle, a copy of which is furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
  
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits
 
99.1
 
Press release of Avadel Pharmaceuticals plc dated as of May 17, 2017.
 
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Avadel Pharmaceuticals plc
By: /s/ Phillandas T. Thompson
Phillandas T. Thompson
Senior Vice President, General Counsel and Corporate Secretary

Date: May 18, 2017
 
Exhibit Index
 
 
99.1
 
Press release of Avadel Pharmaceuticals plc dated as of May 17, 2017.


2
28866715